eyesonmilan / Shutterstock.com
Gilead Sciences, the maker of HIV drug Truvada (emtricitabine/tenofovir), has asked the US Patent and Trademark Office (USPTO) to review patents granted to the government covering preventative use of the drug.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, PrEP, HIV, Truvada, generics, Teva, CDC, innovation, USPTO, IPRs, inter partest reviews, patents